Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Georg A. Bjarnason, Samir Patel et al.|European Urology|2021Cited by 128
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A. Bjarnason, Naveen S. Basappa, Jennifer J. Knox et al.|European Journal of Cancer|2019Cited by 28
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.Patrick Cheung, Georg A. Bjarnason, Samir Patel et al.|Journal of Clinical Oncology|2020Cited by 9
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.Georg A. Bjarnason, Naveen S. Basappa, Jennifer J. Knox et al.|Journal of Clinical Oncology|2017Cited by 7
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).Naveen S. Basappa, Daniel Yick Chin Heng, Aly‐Khan A. Lalani et al.|Journal of Clinical Oncology|2017Cited by 6